Research and Analysis of Drug Resistance Mechanism of HDACi in the Treatment of Skin Melanoma

Ming Yin; Hua Tang; Hao Feng

doi:10.54097/zvejz385

Authors

Ming Yin
Hua Tang
Hao Feng

DOI:

https://doi.org/10.54097/zvejz385

Keywords:

Treatment, Melanoma, Drug Resistance Mechanisms

Abstract

Histone deacetylase inhibitors (HDACi) have shown potential as an epigenetic therapy in various cancer treatments. However, its application in the treatment of skin melanoma faces the challenge of drug resistance. This article reviews the drug resistance mechanism of HDACi in the treatment of skin melanoma, analyzes the mechanism of action of HDACi, the drug resistance characteristics of melanoma, the drug resistance mechanism of HDACi in the treatment of melanoma, and potential solutions to drug resistance, aiming to provide reference for the further application of HDACi in the treatment of skin melanoma.

Downloads

Download data is not yet available.

References

[1] Wu Dan Construction and experimental validation of a prognostic model for skin melanoma related to lipid metabolism genes based on bioinformatics analysis [D]. Mentor: Zhu Xiaohai PLA Naval Medical University, two thousand and twenty-four.

[2] Yang Wenchao Identification of tumor microenvironment related prognostic markers for metastatic cutaneous melanoma based on bioinformatics [D]. Mentor: Zhang Baolin; Qiu Lixia Shanxi Medical University, two thousand and twenty-three.

[3] Luo Yining Prediction of prognosis and therapeutic efficacy of skin melanoma based on necrotic apoptosis related lncRNA [D]. Mentor: Zhang Jianglin Central South University, two thousand and twenty-three.

[4] Pan Yinghao Study on the role of GRP78-GPX4 pathway in enhancing iron death tolerance and promoting migration of melanoma cells in the skin [D]. Mentor: He Yuanmin Southwest Medical University, two thousand and twenty-three.

[5] Dragon triumphs over courage Comprehensive analysis of oncogene AURKA and targeted drug screening in skin melanoma based on bioinformatics and molecular docking technology [D]. Mentor: Zhang Xuanfen Lanzhou University, two thousand and twenty-three.

[6] Zhang Man, Liu Aichun New progress of HDAC inhibitors in the treatment of hematological malignancies [J]. Modern oncology, 2022, 30 (14): 2654-2658.

[7] Ping Shuai Construction and Validation of a Prognostic Model for Iron Death Genes in Skin Melanoma [D]. Mentor: Weizhuo Huazhong University of Science and Technology, two thousand and twenty-two.

[8] Wang Xuliang The therapeutic effect and mechanism of HDACi in heart failure with preserved ejection fraction [D]. Mentor: Tang Yida Peking Union Medical College, two thousand and twenty-two.

[9] Li Guanhu The inhibitory effect of HDACi valproic acid combined with ionizing radiation on the proliferation of breast cancer cells and its mechanism [D]. Supervisor: Wang Zhenqi Jilin University, two thousand and twenty-one.

[10] Chen Xinrui Clinical study on targeted therapy of elderly relapsed refractory B-cell lymphoma with HDACi combined with CD20 monoclonal antibody [D]. Mentor: Wang Huaqing Tianjin Medical University, two thousand and twenty-one.

[11] Premi Sanjay, Qin Yong, Ahmad Nihal. Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma [J]. Frontiers in Oncology, 2022, 12.

[12] Zhulikov Ya. A., Samoylenko I. V., Demidov L. V. Mechanisms of resistance to anti-Pd-1 therapy in metastatic cutaneous melanoma [J]. Russian Journal of Biotherapy, 2018, 17 (1).